諾輝健康 (6606.HK)

14.140 -3.480 (-19.75%) 收市：04:08PM HKT

諾輝健康

T1 Building
13th Floor 400 Jianger Road Binjiang District
Hangzhou 310052
China
86 57 1811 07210
https://ir.newhorizonbio.com

版塊: Healthcare
行業: Medical Devices
全職員工: 1,041

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Yeqing Zhu	CEO, Executive Chairman & Co-founder	10.93M	無	1972
Dr. Yiyou Chen Ph.D.	Executive Director & Chief Scientific Officer	5.63M	無	1972
Mr. Yu Gao	CFO & Joint Company Secretary	無	無	1983
Dr. Ning Lu	Chief Technology Officer	無	無	1971
Ms. Ming-Wai Mok	Joint Company Secretary	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2015 and is headquartered in Hangzhou, China.

公司管治

截至 無 止，諾輝健康 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。